563 related articles for article (PubMed ID: 32700154)
1. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
Lee YR; Yeo S
Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
[TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
3. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
4. Cefiderocol: A Siderophore Cephalosporin.
El-Lababidi RM; Rizk JG
Ann Pharmacother; 2020 Dec; 54(12):1215-1231. PubMed ID: 32522005
[TBL] [Abstract][Full Text] [Related]
5. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
6. Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.
Syed YY
Drugs; 2021 Sep; 81(13):1559-1571. PubMed ID: 34427896
[TBL] [Abstract][Full Text] [Related]
7. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
[TBL] [Abstract][Full Text] [Related]
8. Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.
Parsels KA; Mastro KA; Steele JM; Thomas SJ; Kufel WD
J Antimicrob Chemother; 2021 May; 76(6):1379-1391. PubMed ID: 33532823
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
10. Cefiderocol for Infections Caused by Multidrug-Resistant Gram-Negative Bacteria.
Weaver K; Stallworth K; Blakely KK
Nurs Womens Health; 2020 Oct; 24(5):377-382. PubMed ID: 32890463
[TBL] [Abstract][Full Text] [Related]
11.
Nakamura R; Ito-Horiyama T; Takemura M; Toba S; Matsumoto S; Ikehara T; Tsuji M; Sato T; Yamano Y
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262762
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens.
Jorda A; Zeitlinger M
Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355
[No Abstract] [Full Text] [Related]
13. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
[TBL] [Abstract][Full Text] [Related]
15.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158270
[TBL] [Abstract][Full Text] [Related]
16.
Shortridge D; Streit JM; Mendes R; Castanheira M
Microbiol Spectr; 2022 Apr; 10(2):e0271221. PubMed ID: 35262394
[TBL] [Abstract][Full Text] [Related]
17. Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE).
Chatterjee S; Chakraborty DS; Choudhury S; Lahiry S
Curr Drug Res Rev; 2022; 14(1):20-23. PubMed ID: 34872487
[TBL] [Abstract][Full Text] [Related]
18. [Cefiderocol: a novel siderophore cephalosporin against multi-drug resistant Gram-negative bacilli infections].
Kuai J; Wang X; Wang H
Sheng Wu Gong Cheng Xue Bao; 2022 Mar; 38(3):990-1003. PubMed ID: 35355469
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.
Golden AR; Adam HJ; Baxter M; Walkty A; Lagacé-Wiens P; Karlowsky JA; Zhanel GG
Diagn Microbiol Infect Dis; 2020 May; 97(1):115012. PubMed ID: 32081522
[TBL] [Abstract][Full Text] [Related]
20. Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.
Ong'uti S; Czech M; Robilotti E; Holubar M
Clin Infect Dis; 2022 Apr; 74(7):1303-1312. PubMed ID: 34492098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
